| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Not specifically identified. Likely targets include pathways involved in oxidative stress and inflammation.
|
|---|---|
| ln Vitro |
Alcesefoliside demonstrates cytoprotective activity comparable to silymarin at 60 ug/mL. It exhibits antioxidant activity by scavenging reactive oxygen species, resulting in anti-inflammatory and antioxidant effects.
|
| ln Vivo |
Not specifically reported for this compound. Based on its in vitro cytoprotective and antioxidant activities, it is expected to show hepatoprotective and anti-inflammatory effects in vivo.
|
| Enzyme Assay |
Not specifically reported for this compound. As a flavonoid, it likely acts as an antioxidant by scavenging free radicals and chelating metal ions. Binding assays to specific receptors or enzymes have not been characterized.
|
| Cell Assay |
Cells (e.g., hepatocytes or neuronal cells) are treated with Alcesefoliside and exposed to oxidative stress (e.g., H2O2 or CCl4). Cell viability (MTT assay), reactive oxygen species levels (DCFH-DA), and markers of apoptosis (caspase-3) are measured. Cytoprotective activity is compared to silymarin as a positive control.
|
| Animal Protocol |
Animal models of liver injury (e.g., CCl4-induced hepatotoxicity) or inflammation could be used to assess the in vivo efficacy of Alcesefoliside. Serum liver enzymes (ALT, AST), oxidative stress markers, and histopathological examination of liver tissues would be evaluated.
|
| ADME/Pharmacokinetics |
Predicted to have poor oral bioavailability due to its high molecular weight (756.66) and polar nature (multiple sugar moieties). Likely metabolized by gut microbiota to smaller absorbable metabolites. Plasma half-life is expected to be short.
|
| Toxicity/Toxicokinetics |
No specific toxicity data reported for Alcesefoliside. As a natural flavonoid glycoside, it is expected to have low toxicity. Standard safety pharmacology studies would be required for therapeutic development.
|
| References | |
| Additional Infomation |
Alcesefoliside has been reported to exist in wild peas, American ash, and other organisms for which data are available.
Alcesefoliside is a natural product isolated from various plants. It is used as a research tool for studying cytoprotection, antioxidant defense, and anti-inflammatory mechanisms. It has not been approved for clinical use. The compound's mechanism involves protection of cells from oxidative damage, similar to other flavonoid antioxidants. |
| Molecular Formula |
C33H40O20
|
|---|---|
| Molecular Weight |
756.658700000001
|
| Exact Mass |
756.211
|
| CAS # |
124151-38-8
|
| PubChem CID |
11828754
|
| Appearance |
White to yellow solid powder
|
| Density |
1.79±0.1 g/cm3(Predicted)
|
| Boiling Point |
1090.4±65.0 °C(Predicted)
|
| LogP |
-2.4
|
| Hydrogen Bond Donor Count |
12
|
| Hydrogen Bond Acceptor Count |
20
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
53
|
| Complexity |
1300
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)O)O[C@H]6[C@@H]([C@@H]([C@H]([C@@H](O6)C)O)O)O)O)O)O)O)O
|
| InChi Key |
HKNBJSRIYRDSLB-MIORVHIISA-N
|
| InChi Code |
InChI=1S/C33H40O20/c1-9-19(38)23(42)26(45)31(48-9)47-8-17-21(40)25(44)30(53-32-27(46)24(43)20(39)10(2)49-32)33(51-17)52-29-22(41)18-15(37)6-12(34)7-16(18)50-28(29)11-3-4-13(35)14(36)5-11/h3-7,9-10,17,19-21,23-27,30-40,42-46H,8H2,1-2H3/t9-,10-,17+,19-,20-,21-,23+,24+,25-,26+,27+,30+,31+,32-,33-/m0/s1
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-3-[(2S,3R,4S,5R,6R)-4,5-dihydroxy-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxychromen-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3216 mL | 6.6080 mL | 13.2160 mL | |
| 5 mM | 0.2643 mL | 1.3216 mL | 2.6432 mL | |
| 10 mM | 0.1322 mL | 0.6608 mL | 1.3216 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
